LGT Fund Management Co Ltd. Sells 226 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

LGT Fund Management Co Ltd. lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,177 shares of the pharmaceutical company’s stock after selling 226 shares during the period. LGT Fund Management Co Ltd.’s holdings in Vertex Pharmaceuticals were worth $474,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Focus Financial Network Inc. increased its position in shares of Vertex Pharmaceuticals by 7.1% during the 3rd quarter. Focus Financial Network Inc. now owns 558 shares of the pharmaceutical company’s stock worth $260,000 after purchasing an additional 37 shares during the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Vertex Pharmaceuticals by 6.5% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 475 shares of the pharmaceutical company’s stock valued at $223,000 after acquiring an additional 29 shares during the period. Van ECK Associates Corp lifted its position in shares of Vertex Pharmaceuticals by 4.5% during the 3rd quarter. Van ECK Associates Corp now owns 151,428 shares of the pharmaceutical company’s stock valued at $71,179,000 after acquiring an additional 6,588 shares during the period. Intact Investment Management Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $326,000. Finally, Vestor Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 16.4% during the 3rd quarter. Vestor Capital LLC now owns 362 shares of the pharmaceutical company’s stock worth $168,000 after buying an additional 51 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares in the company, valued at $29,438,776.43. The trade was a 0.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 1,084 shares of company stock worth $505,512 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on VRTX shares. Piper Sandler lowered their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a report on Monday, January 27th. UBS Group raised their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. JPMorgan Chase & Co. cut their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. Finally, Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $506.70.

Vertex Pharmaceuticals Trading Up 0.7 %

Shares of VRTX stock opened at $483.31 on Tuesday. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $441.95 and a two-hundred day moving average price of $461.06. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a market cap of $124.11 billion, a P/E ratio of -219.69, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.